The Delhi High Court recently issued a critical directive to Fortis Healthcare Ltd (FHL) regarding its accountability for disappearing shares. Specifically, the court questioned FHL over the dissipation of shares previously held by its former promoters, Malvinder and Shivinder Singh. This long-standing legal battle, widely known as the Fortis liability case, continues to draw significant attention from healthcare professionals and corporate administrators across India.

Core Issues in the Dispute

The core dispute centers on 38.3 million shares of FHL. Originally, these shares formed the foundation of a massive international arbitration award. Japanese pharmaceutical giant Daiichi Sankyo has been pursuing this award for over a decade. Consequently, the legal claim has now swelled to a staggering Rs 5,200 crore. In the recent hearings, the court made it clear that Fortis Healthcare cannot shift its ownership responsibilities onto third parties. Justice Subramonium Prasad noted that FHL should have intervened to stop the sale of these shares when they were first liquidated.

Understanding Court Observations on Liability

Historically, the Singh brothers allegedly divested these shares in a series of transactions while the arbitration was active. Therefore, the court has taken a strict stance on asset preservation. Justice Prasad remarked that because these were FHL's shares, FHL remains ultimately responsible. This case has practically evolved into a complex three-way legal contest involving the Singh brothers, 16 banking institutions, and FHL. Furthermore, Daiichi Sankyo is pushing for a forensic audit to examine how these assets dwindled so significantly. In response, FHL's legal team intends to file a perjury application against Daiichi Sankyo, which will likely intensify the ongoing litigation.

Crucial Updates on the Fortis Liability Case

Indeed, the judiciary is treating this case with immense gravity. The Delhi High Court has conducted 48 back-to-back hearings since December 2025. Legal experts suggest that this rapid schedule highlights the judiciary's commitment to enforcing international arbitral awards. Additionally, the outcome of this case could establish critical precedents for corporate governance and regulatory compliance within the Indian healthcare industry.

Frequently Asked Questions

Q1: Why is the Delhi High Court holding Fortis Healthcare Ltd responsible?

The court stated that Fortis Healthcare Ltd should have prevented the sale of its promoter shares. Because FHL allowed these shares to slip away, it cannot now deflect the liability onto any third party.

Q2: What is the total value of the arbitral award involved in this dispute?

The original arbitration award obtained by Daiichi Sankyo against the Singh brothers has now grown to approximately Rs 5,200 crore over the last decade.

Q3: What legal actions are the parties taking next?

Daiichi Sankyo is seeking a forensic audit of Fortis Healthcare Ltd and the involved banks. Meanwhile, Fortis Healthcare's legal counsel plans to file a perjury application against Daiichi Sankyo.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Fortis liability case: Delhi HC says blame can't be shifted to third party - ETHealthworld


2. Delhi High Court Finds Fortis Healthcare Liable for Disappearing Promoter Shares - Business and Legal Reports


3. Fortis Healthcare secures rights to Fortis brand in public auction - Business Standard